sorafenib has been researched along with arylomycin a-c16 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (arylomycin a-c16) | Trials (arylomycin a-c16) | Recent Studies (post-2010) (arylomycin a-c16) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7 | 0 | 7 |
| Protein | Taxonomy | sorafenib (IC50) | arylomycin a-c16 (IC50) |
|---|---|---|---|
| Signal peptidase I | Escherichia coli K-12 | 0.07 | |
| Signal peptidase IB | Staphylococcus aureus | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benediktsdottir, A; Karlén, A; Mowbray, SL; Rusin, D; Szałaj, N; Więckowska, A | 1 |
1 review(s) available for sorafenib and arylomycin a-c16
| Article | Year |
|---|---|
Bacterial type I signal peptidase inhibitors - Optimized hits from nature.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Proteins; Membrane Proteins; Serine Endopeptidases | 2022 |